{"entity":{"id":"michael-postow","kind":"person","name":"Michael A. Postow","aka":[],"tldr":"Led CheckMate 069, the first randomised trial of nivolumab plus ipilimumab, and defines how to manage immunotherapy side effects.","summary":"Michael Postow led CheckMate 069, the randomised phase 2 trial that first showed nivolumab plus ipilimumab dramatically improves response rates over ipilimumab alone in melanoma and set up CheckMate 067. He wrote the widely cited NEJM review of immune-related adverse events and leads trials of adaptive dosing and treatment discontinuation. He chairs the melanoma service at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Postow%20MA%5BAuthor%5D%20melanoma%20immune"}],"tags":["melanoma","immunotherapy","toxicity"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","ctla4"],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["checkmate-067"],"people":[],"bottlenecks":[],"keyPapers":["paper-asco-irae-guideline-jco-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Melanoma","Immunotherapy","Immune-related adverse events","Treatment duration"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Postow%20MA%5BAuthor%5D%20melanoma%20immune"}],"papers":[{"title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma (CheckMate 069)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1414428"},{"title":"Immune-related adverse events associated with immune checkpoint blockade","journal":"NEJM","year":2018,"doi":"10.1056/NEJMra1703481"},{"title":"ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors","journal":"Journal of Clinical Oncology","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Management%20of%20Immune-Related%20Adverse%20Events%20ASCO%20Guideline%20Update%20Schneider%20JCO%202021"}]},"route":"/people/michael-postow/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/"}],"paper":[{"id":"paper-asco-irae-guideline-jco-2021","kind":"paper","name":"ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors","route":"/key-papers/paper-asco-irae-guideline-jco-2021/"}]}}